Idera Pharmaceuticals, Inc.(NASDAQ : IDRA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading IDRA News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.29%||72.68||1.2%||$696.93m|
|REGN||Regeneron Pharmaceuticals, Inc.||-3.57%||355.80||3.6%||$379.95m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.15%||124.35||1.9%||$361.62m|
|VRTX||Vertex Pharmaceuticals Incorporated||-3.66%||75.26||2.9%||$163.89m|
|IONS||Ionis Pharmaceuticals, Inc.||-4.26%||45.43||10.0%||$146.45m|
|BMRN||BioMarin Pharmaceutical Inc.||-2.04%||81.30||4.5%||$113.90m|
|BLUE||Bluebird Bio, Inc.||-9.37%||71.55||23.3%||$112.28m|
|A||Agilent Technologies, Inc.||-0.41%||44.66||1.6%||$111.16m|
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.